FoxM1: Repurposing an oncogene as a biomarker

Nandi, Deeptashree; Cheema, Pradeep Singh; Jaiswal, Neha; Nag, Alo

doi:10.1016/j.semcancer.2017.08.009

Cited by 109 publications

(85 citation statements)

References 190 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, an increasing number of studies have focused on the development of accurate molecular biomarkers for better detection, diagnosis, prognosis, and treatment (18)(19)(20). For instance, forkhead transcription factor (FoxM1) functions as an oncogene in the initiation, development, and progression of cancer, and its neoplastic functions can be used as a strong biomarker for the diagnosis and treatment of cancer (21). In prostate cancer, numerous prognostic biomarkers were also investigated (22)(23)(24).…”

Section: Discussionmentioning

confidence: 99%

Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells in�vitro

Qian

Yang

2019

Exp Ther Med

View full text Add to dashboard Cite

CD81, a member of the tetraspanin family, has been revealed to be upregulated and associated with prognosis in several types of cancer; however, this relationship has not been explored in prostate cancer. The present study aimed to investigate the prognostic significance and functional role of CD81 in prostate cancer. The expression of CD81 in prostate cancer tissues and cell lines was evaluated using qRT-PCR analysis. Kaplan-Meier survival analysis and Cox regression analysis were conducted to explore the prognostic significance of CD81. Cell experiments were used to explore the effects of CD81 on cell proliferation, migration, and invasion in prostate cell lines in vitro. The expression of CD81 was increased in both prostate cancer tissues and cell lines. Upregulation of CD81 was significantly associated with lymph node metastasis and TNM stage. Moreover, patients with high CD81 levels had poorer overall survival than those with lower levels. Additionally, tumor cell proliferation, migration, and invasion were inhibited by knockdown of CD81. The present results indicated that CD81 plays an oncogenic role in prostate cancer. Overexpression of CD81 may serve as a prognostic biomarker and therapeutic target and is involved in the progression of prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells in�vitro

Qian

Yang

2019

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…In agreement, E2F1, E2F2, E2F8, and FOXM1 displayed a significant decrease upon radiation. FOXM1 and E2F factors have been previously implicated in chromatin remodeling, cell cycle regulation, DNA repair, and radio-resistance [45,46]. All four factors are highly expressed in glioblastoma with respect to low-grade glioma.…”

Section: Resultsmentioning

confidence: 99%

Integrated analyses of early responses to radiation in glioblastoma identify new alterations in RNA processing and candidate target genes to improve treatment outcomes

Choudhary

Burns

Mirsafian

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: High-dose radiation is the main component of glioblastoma therapy. Unfortunately, radioresistance is a common problem and a major contributor to tumor relapse. Understanding the molecular mechanisms driving response to radiation is critical for identifying regulatory routes that could be targeted to improve treatment response. Methods:We conducted an integrated analysis in the U251 and U343 glioblastoma cell lines to map early alterations in the expression of genes at three levels: transcription, splicing, and translation in response to ionizing radiation.Results: Changes at the transcriptional level were the most prevalent response. Downregulated genes are strongly associated with cell cycle and DNA replication and linked to a coordinated module of expression.Alterations in this group are likely driven by decreased expression of the transcription factor FOXM1 and members of the E2F family. Genes involved in RNA regulatory mechanisms were affected at the mRNA, splicing, and translation levels, highlighting their importance in radiation-response. We identified a number of oncogenic factors, with an increased expression upon radiation exposure, including BCL6, RRM2B, IDO1, FTH1, APIP, and LRIG2 and lncRNAs NEAT1 and FTX. Several of these targets have been previously implicated in radioresistance. Therefore, antagonizing their effects post-radiation could increase therapeutic efficacy. Conclusions:Our integrated analysis provides a comprehensive view of early response to radiation in glioblastoma. We identify new biological processes involved in altered expression of various oncogenic factors and suggest new target options to increase radiation sensitivity and prevent relapse.

show abstract

“…Forkhead box M1 (FOXM1) was a proliferation‐associated transcription factor, which has different functions in tumorigenesis and its elevated levels were generally associated with cancer progression (Guo et al, ; Milewski et al, ). Studies have showed that FOXM1 was one of the most common overexpressed genes in human solid tumors (Nandi, Cheema, Jaiswal, & Nag, ), including ccRCC (Xue et al, ). Several studies have recorded that FOXM1 expression was significantly correlated with primary tumor stage and an aggressive phenotype of ccRCC, which was consistent with our previous results (Wu et al, ; Xue et al, ).…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of a gene signature in clear cell renal cell carcinoma

Liang

Luo

Wang

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Renal cancer is a common urogenital system malignance. Novel biomarkers could provide more and more critical information on tumor features and patients’ prognosis. Here, we performed an integrated analysis on the discovery set and established a three‐gene signature to predict the prognosis for clear cell renal cell carcinoma (ccRCC). By constructing a LASSO Cox regression model, a 3‐messenger RNA (3‐mRNA) signature was identified. Based on the 3‐mRNA signature, we divided patients into high‐ and low‐risk groups, and validated this by using three other data sets. In the discovery set, this signature could successfully distinguish between the high‐ and low‐risk patients (hazard ratio (HR), 2.152; 95% confidence interval (CI),1.509–3.069; p < 0.0001). Analysis of internal and two external validation sets yielded consistent results (internal: HR, 2.824; 95% CI, 1.601–4.98; p < 0.001; GSE29609: HR, 3.002; 95% CI, 1.113–8.094; p = 0.031; E‐MTAB‐3267: HR, 2.357; 95% CI, 1.243–4.468; p = 0.006). Time‐dependent receiver operating characteristic (ROC) analysis indicated that the area under the ROC curve at 5 years was 0.66 both in the discovery and internal validation set, while the two external validation sets also suggested good performance of the 3‐mRNA signature. Besides that, a nomogram was built and the calibration plots and decision curve analysis indicated the good performance and clinical utility of the nomogram. In conclusion, this 3‐mRNA classifier proved to be a useful tool for prognostic evaluation and could facilitate personalized management of ccRCC patients.

show abstract

FoxM1: Repurposing an oncogene as a biomarker

Cited by 109 publications

References 190 publications

Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells in�vitro

Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells in�vitro

Integrated analyses of early responses to radiation in glioblastoma identify new alterations in RNA processing and candidate target genes to improve treatment outcomes

Prognostic value of a gene signature in clear cell renal cell carcinoma

Contact Info

Product

Resources

About